内镜超声引导腹腔神经丛毁损术联合或不联合布比卡因的随机对照试验方案
本研究为单中心、随机、双盲对照试验,纳入不可手术的腹腔神经丛受累恶性肿瘤(胰腺癌或其他)患者,比较内镜超声引导腹腔神经丛毁损术(EUS-CPN)联合或不联合布比卡因的疗效。研究假设布比卡因可能因稀释酒精的神经毁损作用而降低疼痛控制效果,且不慎血管内注射可能引发心律失常和心脏骤停等严重不良事件。
要点
- EUS-CPN通常先注射布比卡因再注射无水酒精。
- 研究假设布比卡因可能多余并降低疼痛控制效果。
- 布比卡因不慎血管内注射可能导致严重不良事件。
核心结论
- 本随机试验旨在评估布比卡因在EUS-CPN中是否有价值。
研究设计与样本
- 单中心、随机、双盲对照试验,比较EUS-CPN联合或不联合布比卡因在不可手术的腹腔神经丛受累恶性肿瘤(胰腺癌或其他)患者中的应用。
- 研究经研究伦理委员会批准,批准号为2022-9969和21.151,并在ClinicalTrials.gov注册(NCT04951804)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pancreatic cancer is a devastating disease with less than 5% 5-year survival. Inoperable patients often present with pain. Randomized controlled trial have shown that endoscopic ultrasound-guided celiac plexus neurolysis (EUS-CPN) improves pain control. It is usually performed by injecting bupivacaine followed by absolute alcohol around the celiac axis. STUDY DESIGN: Single center, randomized, double blind controlled trial of EUS-CPN with and without bupivacaine in patients with inoperable malignancy (pancreatic or other) involving the celiac plexus. The study was approved by research ethics board with approval number of 2022-9969, 21.151 and registered on ClinicalTrials.gov (NCT04951804). DISCUSSION: We hypothesize that bupivacaine is superfluous and may actually reduce pain control by diluting the neurolytic effect of alcohol. Bupivacaine is also potentially dangerous in that it may produce serious adverse events such as arrythmias and cardiac arrest if inadvertently injected intravascularly. CONCLUSION: This randomized trial is designed to assess whether bupivacaine is of any value during EUS-CPN.
引用
- Esmail E, Paquin SC, Sahai AV, et al. Protocol for a randomized controlled trial of endoscopic ultrasound guided celiac plexus neurolysis (EUS-CPN) with vs without bupivacaine. Trials. 2023. PMID: 37684697. doi:10.1186/s13063-023-07487-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。